Highlights

PharmaVOICE interview with Cameron Durrant

In an exclusive interview with PharmaVOICE's Editor Taren Grom, Cameron Durrant, M.D., current CEO and chairman of KaloBios, talks about taking the helm of the embattled small biotech company amid ...

KaloBios Corporate Presentation

The KaloBios Pharmaceuticals, Inc corporate presentation is available for stakeholders and investors to download, providing an insight into the Company’s value model, vision and execution mindset of a highly experienced ...

San Francisco Business Times – BioFlash Podcast

It was a nice thing — and a great PR move — when Allergan plc CEO Brent Saunders earlier this month blogged about his responsible pricing pledge. Cameron Durrant’s been there, done that. Five months ...

KaloBios Emerges from Chapter 11 Bankruptcy

KaloBios Pharmaceuticals, Inc. (OTC:KBIOQ), a developmental stage biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has emerged from Chapter 11 bankruptcy ...

ISNTD Q&A interview

By Kamran Rafiq

In this exclusive International Society for Neglected Tropical Diseases (ISNTD) interview, Dr. Durrant talks about the adoption of a new pricing model that will guide ...

The Bio Report Interview

By Danny Levine

In April, the development-stage company unveiled a pricing plan based on transparency, affordability, and reasonable profit. We spoke to Cameron Durrant, CEO of KaloBios, about ...